Completed PHASE4 INTERVENTIONAL 1-arm NCT01270087

The Effect of Adalimumab (Humira) on Vascular Abnormalities in Rheumatoid Arthritis. A Pilot Study.

Sponsor: Abbott

Interventions Adalimumab

Updated 7 times since 2017 Last updated: Jan 4, 2011 Started: May 31, 2005 Primary completion: Feb 28, 2007 Completion: Feb 28, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Rheumatoid Arthritis, this trial is completed. The trial is conducted by Abbott and has accumulated 7 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Aug 2017 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Feb 2017 — Aug 2017 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

May 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abbott
Crafoord Foundation
Skane University Hospital
The Swedish Research Council
The Swedish Rheumatism Ass

Data source: Skane University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Malmo, Sweden